HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a $42 price target on the stock.
December 19, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reaffirmed a Buy rating on Crinetics Pharmaceuticals with a $42 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and the maintenance of a $42 price target by a reputable analyst could lead to increased investor confidence and a potential short-term uptick in CRNX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100